TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective

  1. Masanori Oshi
  2. Makoto Sugimori
  3. Kei Kawashima
  4. Shipra Gandhi
  5. Akimitsu Yamada
  6. Kazutaka Narui
  7. Takashi Ishikawa
  8. Itaru Endo
  9. Kazuaki Takabe
Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1186/s13058-026-02305-9
  2. Version published to 10.21203/rs.3.rs-8082446/v1 on Research Square